BRPI0822044A2 - Combinação de uma proteina de fusão anti anticorpo para edb da fibronectina-il-2 e uma molécula de ligação a células b, progenitores de células b e/ou seu correspondente canceroso - Google Patents

Combinação de uma proteina de fusão anti anticorpo para edb da fibronectina-il-2 e uma molécula de ligação a células b, progenitores de células b e/ou seu correspondente canceroso

Info

Publication number: BRPI0822044A2
Authority: BR; Brazil
Prior art keywords: cell; combination; fusion protein; edb; fibronectin
Prior art date: 2008-01-17

Application number

BRPI0822044-1A

Other languages

English (en)

Inventor

Dario Neri

Hans Dietrich Menssen

Andreas Menrad

Christoph Schliemann

Original Assignee

Philogen Spa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-01-17

Filing date

2008-11-08

Publication date

2015-07-28

2008-11-08 Application filed by Philogen Spa filed Critical Philogen Spa

2015-07-28 Publication of BRPI0822044A2 publication Critical patent/BRPI0822044A2/pt

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/44—Antibodies bound to carriers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Cell Biology (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Mycology (AREA)
Microbiology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Hematology (AREA)
Oncology (AREA)
Optics & Photonics (AREA)
Physics & Mathematics (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Biomedical Technology (AREA)
Toxicology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Diabetes (AREA)
Transplantation (AREA)
Pain & Pain Management (AREA)

BRPI0822044-1A 2008-01-17 2008-11-08 Combinação de uma proteina de fusão anti anticorpo para edb da fibronectina-il-2 e uma molécula de ligação a células b, progenitores de células b e/ou seu correspondente canceroso BRPI0822044A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP08075044A EP2085095B1 (en)	2008-01-17	2008-01-17	Combination of an anti-EDb fibronectin antibody-IL-2 fusion protein, and a molecule binding to B cells, B cell progenitors and/or their cancerous counterpart
PCT/EP2008/009441 WO2009089858A1 (en)	2008-01-17	2008-11-08	COMBINATION OF AN ANTI-EDb FIBRONECTIN ANTIBODY-IL-2 FUSION PROTEIN, AND A MOLECULE BINDING TO B CELLS, B CELL PROGENITORS AND/OR THEIR CANCEROUS COUNTERPART

Publications (1)

Publication Number	Publication Date
BRPI0822044A2 true BRPI0822044A2 (pt)	2015-07-28

Family

ID=39427510

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0822044-1A BRPI0822044A2 (pt)	2008-01-17	2008-11-08	Combinação de uma proteina de fusão anti anticorpo para edb da fibronectina-il-2 e uma molécula de ligação a células b, progenitores de células b e/ou seu correspondente canceroso

Country Status (13)

Country	Link
US (3)	US20100310454A1 (pt)
EP (1)	EP2085095B1 (pt)
JP (1)	JP5140164B2 (pt)
KR (1)	KR20100113572A (pt)
CN (1)	CN101969980A (pt)
AT (1)	ATE548052T1 (pt)
AU (1)	AU2008347450B2 (pt)
BR (1)	BRPI0822044A2 (pt)
CA (1)	CA2711902C (pt)
ES (1)	ES2382058T3 (pt)
MX (1)	MX2010007716A (pt)
RU (1)	RU2484845C2 (pt)
WO (1)	WO2009089858A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2085095B1 (en)	2008-01-17	2012-03-07	Philogen S.p.A.	Combination of an anti-EDb fibronectin antibody-IL-2 fusion protein, and a molecule binding to B cells, B cell progenitors and/or their cancerous counterpart
WO2010078945A2 (en) *	2009-01-07	2010-07-15	Philogen S.P.A.	Cancer treatment
AR078161A1 (es)	2009-09-11	2011-10-19	Hoffmann La Roche	Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
CN105440123B (zh)	2011-02-10	2020-10-09	罗切格利卡特公司	突变体白介素-2多肽
RU2013139267A (ru) *	2011-02-10	2015-03-20	Рош Гликарт Аг	Улучшенная иммунотерапия
EA201892619A1 (ru)	2011-04-29	2019-04-30	Роше Гликарт Аг	Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
WO2017107914A1 (zh) *	2015-12-21	2017-06-29	合肥立方制药股份有限公司	一种药物设计方法和获得的药物及其应用
IL310865A (en) *	2016-10-17	2024-04-01	Pfizer	Antibodies against EDB and antibody-drug conjugates
GB201621806D0 (en)	2016-12-21	2017-02-01	Philogen Spa	Immunocytokines with progressive activation mechanism
KR102920712B1 (ko)	2017-05-24	2026-01-30	노파르티스 아게	항체-사이토카인 생착된 단백질 및 암 치료에 있어서의 사용 방법
WO2020070150A1 (en)	2018-10-02	2020-04-09	Philogen S.P.A	Il2 immunoconjugates
EP3660039A1 (en)	2018-11-30	2020-06-03	Philogen S.p.A.	Il2 immunoconjugates
WO2020249757A1 (en)	2019-06-14	2020-12-17	Philogen S.P.A	Immunoconjugates comprising a single chain diabody and interleukin-15 or interleukin-15 and a sushi domain of interleukin-15 receptor alpha
KR102614063B1 (ko)	2020-12-24	2023-12-19	대화제약 주식회사	엑스트라도메인 b 피브로넥틴에 특이적으로 결합하는 신규한 항체
MX2024011514A (es) *	2022-03-23	2024-09-24	Philogen Spa	Preparacion de un inmunoconjugado de il2.
AU2023332212A1 (en)	2022-09-01	2025-04-10	Philogen S.P.A.	Tnf alpha and interleukin-2 combination therapy for non-melanoma skin cancer
EP4780495A1 (en)	2023-09-19	2026-07-29	Philochem AG	Therapeutic combination of an anti-edb fibronectin domain antibody il2 or il12 fusion protein and a lutetium-177 radioconjugate
WO2026003203A1 (en)	2024-06-27	2026-01-02	Philogen S.P.A.	Combination of an immunocytokine comprising targeted il2 and a jak inhibitor

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FI82266C (fi)	1982-10-19	1991-02-11	Cetus Corp	Foerfarande foer framstaellning av il-2 -mutein.
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
WO1985000817A1 (en)	1983-08-10	1985-02-28	Amgen	Microbial expression of interleukin ii
US5243029A (en) *	1986-04-09	1993-09-07	Fred Hutchinson Cancer Research Center	Oncofetal structure of fibronectin
JPH02500329A (ja)	1987-05-21	1990-02-08	クリエイテイブ・バイオマリキユールズ・インコーポレーテツド	ターゲット化多機能蛋白質
DE3920358A1 (de)	1989-06-22	1991-01-17	Behringwerke Ag	Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
CA2100671C (en)	1991-02-27	1999-02-02	James S. Huston	Serine rich peptide linkers
DE69233528T2 (de)	1991-11-25	2006-03-16	Enzon, Inc.	Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
CA2126967A1 (en)	1992-11-04	1994-05-11	Anna M. Wu	Novel antibody construct
ATE139900T1 (de)	1992-11-13	1996-07-15	Idec Pharma Corp	Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US5736137A (en)	1992-11-13	1998-04-07	Idec Pharmaceuticals Corporation	Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
CA2226575C (en)	1995-07-27	2011-10-18	Genentech, Inc.	Stabile isotonic lyophilized protein formulation
GB9610967D0 (en) *	1996-05-24	1996-07-31	Cambridge Antibody Tech	Specific binding members,materials and methods
ATE230277T1 (de)	1997-06-13	2003-01-15	Genentech Inc	Stabilisierte antikörperformulierung
US20030176663A1 (en) *	1998-05-11	2003-09-18	Eidgenossische Technische Hochscule	Specific binding molecules for scintigraphy
TWI259837B (en)	1998-05-11	2006-08-11	Eidgenossische Tech Hochscule	Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
US20030045681A1 (en) *	1998-05-11	2003-03-06	Anthony J. Zelano	Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
US8623373B2 (en) *	2000-02-24	2014-01-07	Philogen S.P.A.	Compositions and methods for treatment of angiogenesis in pathological lesions
US20020197700A1 (en) *	2000-09-07	2002-12-26	Schering Ag	Receptor of the EDb-fibronectin domains
AU2002362098A1 (en) *	2001-12-07	2003-06-23	Chiron Corporation	Methods of therapy for non-hodgkin's lymphoma
ES2337566T3 (es)	2002-03-11	2010-04-27	Philogen S.P.A.	Anticuerpos derivados de anti ed-b l19 y vasculatura tumoral objetivo.
EP1514561A1 (en) *	2003-09-10	2005-03-16	Philogen S.p.A.	Targeting of tumor vasculature using radiolabelled antibody L19 against fibronectin ED-B
BRPI0607351A2 (pt) *	2005-02-15	2009-09-01	Novartis Vaccines & Diagnostic	métodos para tratamento de linfomas empregando uma combinação de agente quimioterapêutico e il-2 e opcionalmente um anticorpo anti-cd20
EP1842553A1 (en) *	2006-04-07	2007-10-10	Bayer Schering Pharma Aktiengesellschaft	Combination of an anti-EDb fibronectin domain antibody/IL2 fusion protein and a further small molecule
EP2036576A1 (en) *	2007-09-17	2009-03-18	Bayer Schering Pharma Aktiengesellschaft	ED-B fibronectin as stratification marker for antitumor drugs
EP2085095B1 (en)	2008-01-17	2012-03-07	Philogen S.p.A.	Combination of an anti-EDb fibronectin antibody-IL-2 fusion protein, and a molecule binding to B cells, B cell progenitors and/or their cancerous counterpart

2008
- 2008-01-17 EP EP08075044A patent/EP2085095B1/en not_active Not-in-force
- 2008-01-17 ES ES08075044T patent/ES2382058T3/es active Active
- 2008-01-17 AT AT08075044T patent/ATE548052T1/de active
- 2008-11-08 JP JP2010542524A patent/JP5140164B2/ja not_active Expired - Fee Related
- 2008-11-08 CA CA2711902A patent/CA2711902C/en not_active Expired - Fee Related
- 2008-11-08 AU AU2008347450A patent/AU2008347450B2/en not_active Ceased
- 2008-11-08 RU RU2010134360/15A patent/RU2484845C2/ru not_active IP Right Cessation
- 2008-11-08 MX MX2010007716A patent/MX2010007716A/es active IP Right Grant
- 2008-11-08 BR BRPI0822044-1A patent/BRPI0822044A2/pt not_active IP Right Cessation
- 2008-11-08 WO PCT/EP2008/009441 patent/WO2009089858A1/en not_active Ceased
- 2008-11-08 CN CN2008801249387A patent/CN101969980A/zh active Pending
- 2008-11-08 KR KR1020107018174A patent/KR20100113572A/ko not_active Ceased
- 2008-11-08 US US12/863,417 patent/US20100310454A1/en not_active Abandoned
- 2008-11-13 US US12/270,174 patent/US8796426B2/en not_active Expired - Fee Related
2014
- 2014-06-17 US US14/306,992 patent/US9289470B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US9289470B2 (en)	2016-03-22
WO2009089858A1 (en)	2009-07-23
EP2085095B1 (en)	2012-03-07
KR20100113572A (ko)	2010-10-21
RU2010134360A (ru)	2012-02-27
JP2011509953A (ja)	2011-03-31
US20140294723A1 (en)	2014-10-02
EP2085095A1 (en)	2009-08-05
US8796426B2 (en)	2014-08-05
ES2382058T3 (es)	2012-06-04
RU2484845C2 (ru)	2013-06-20
AU2008347450B2 (en)	2013-07-25
CA2711902A1 (en)	2009-07-23
CA2711902C (en)	2017-07-18
CN101969980A (zh)	2011-02-09
US20100310454A1 (en)	2010-12-09
JP5140164B2 (ja)	2013-02-06
MX2010007716A (es)	2010-08-04
AU2008347450A1 (en)	2009-07-23
ATE548052T1 (de)	2012-03-15
US20090202473A1 (en)	2009-08-13

Legal Events

Date	Code	Title	Description
2017-09-05	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
2017-12-26	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2435 DE 05-09-2017 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.
2018-03-27	B15K	Others concerning applications: alteration of classification	Ipc: A61K 38/20 (2006.01), A61K 39/395 (2006.01), A61K

Publication	Publication Date	Title
MX2010007716A (es)	2010-08-04	Combinacion de una proteina de fusion del anticuerpo-il-2 de anti-edb fibronectina y una molecula que se une a celulas b, progenitores de la celula b y/o sus contrapartes cancerigenas.
LTPA2017019I1 (lt)	2017-07-10	Žmogaus antikūnai, pasižymintys dideliu giminingumu PCSK9
CY1121818T1 (el)	2020-07-31	Πυρρολοβενζοδιαζεπινες και συζευγματα αυτων
PY09025528A (es)	2016-03-01	Polipéptidos g-csf de bovino modificados y sus usos
BRPI0919186A2 (pt)	2017-01-17	aparelhos de barbear ou depilar e cartuchos.
EA201000888A1 (ru)	2010-12-30	4-фенилпиран-3,5-дионы, 4-фенилтиопиран-3,5-дионы и 2-фенилциклогексан-1,3,5-трионы в качестве гербицидов
EA201000146A1 (ru)	2010-08-30	Связующее майларда на основе гидроксимонокарбоновой кислоты
BRPI0811993A2 (pt)	2014-11-18	" hetarilanilinas como moduladores para beta-amiloide ".
BRPI0917000A2 (pt)	2016-02-16	proteínas conjugadas com eficácia in vivo prolongada
PH12016500081A1 (en)	2017-01-16	Immunoglobulin variants and uses thereof
BRPI0809583A2 (pt)	2019-09-03	polipeptídeos fgf-21 modificados e seus usos
MY197840A (en)	2023-07-20	Cross-linkers and their uses
WO2010036964A3 (en)	2010-07-15	Modified animal erythropoietin polypeptides and their uses
HRP20181977T1 (hr)	2019-01-25	Membranski modul s kliznim priključcima
CL2009001263S1 (es)	2009-10-16	Maquina de afeitar.
WO2009067636A3 (en)	2010-01-21	Modified insulin polypeptides and their uses
WO2006105338A3 (en)	2007-03-29	Fc VARIANTS WITH OPTIMIZED PROPERTIES
BR112013000630A2 (pt)	2016-05-24	imunoglobulinas de domínio variável duplo e usos das mesmas.
ECSP109878A (es)	2010-02-26	Anticuerpos anti-cd79b e inmunoconjugados y métodos de uso de los mismos
CA2705357C (en)	2018-10-23	Formulations for taci-immunoglobulin fusion proteins
EP2507267A4 (en)	2013-05-29	COMPOSITIONS AND METHODS FOR INCREASING THE SERUM DURABILITY OF FC FUSION PROTEINS
MX2010001247A (es)	2010-03-01	Agentes de imagenologia optica.
BRPI0911556A2 (pt)	2016-11-01	eletrodo enzimático, e, célula de combustível.
CL2009001363S1 (es)	2009-10-16	Pieza para maquina de afeitar.
WO2010014922A3 (en)	2010-05-06	Protein purification tags and uses thereof